Edgar Filing: VIRAGEN INC - Form NT 10-K

VIRAGEN INC Form NT 10-K September 28, 2007 (Check One):

UNITED STATES

x Form 1	0-K SECURITIES AND EXCHANGE COMMISSION						
" Form 20)-F Washington, D.C. 20549	SEC File Number CUSIP Number	001-15823 927638403				
" Form 1	I-K						
" Form 10	FORM 12b-25						
" Form N	-SAR						
" Form N-CSR							
	For Period Ended: June 30, 2007						
	Transition Report on Form 10-K	Transition Report on Form 10-K					
	Transition Report on Form 20-F Transition Report on Form 11-K						
	Transition Report on Form 10-Q Transition Report on Form N-SAR						
	For the Transition Period Ended:	For the Transition Period Ended:					
	ing in this form shall be construed to imply that the Commission has verified any inform in this form shall be construed to imply that the Commission has verified any information in this form shall be construed to imply that the Commission has verified any information in this form shall be construed to imply that the Commission has verified any information in this form shall be construed to imply that the Commission has verified any information in this form shall be construed to imply that the Commission has verified any information in this form shall be construed to imply that the Commission has verified any information in the filling checked above, identify the Item(s) to which the notification is a superior of the filling checked above, identify the Item(s) to which the notification is a superior of the filling checked above.		in.				
	PART I REGISTRANT INFORMATION						
_	Viragen, Inc.						
	Full Name of Registrant						
865 S.W. 78 th Avenue, Suite 100							
_	Address of Principal Executive Office (Street and Number)						
_	Plantation, Florida 33324						

City, State and Zip Code

Edgar Filing: VIRAGEN INC - Form NT 10-K

PART II RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate).

- (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
- x (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F,11-K or Form N-SAR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and
 - (c) The accountant s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III NARRATIVE

State below in reasonable detail the reasons why the Form 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof could not be filed within the prescribed time period.

Due to delays attributable to personnel and financial constraints, the registrant is unable to complete preparation of its financial statements and footnotes by the filing date and is unable to currently estimate when it will complete and file its Form 10K.

PART IV OTHER INFORMATION

Name and telephone number of person to contact in regard to this notification

Dennis W. Healey (954) 233-8746

(Name) (Area Code) (Telephone Number)

- (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). x Yes "No
- (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? "Yes x No

 If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

Viragen, Inc.

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 28, 2007

By: /s/ Dennis W. Healey

Executive Vice President

Principal Financial Officer